Drugs / EB-DART-NK01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07480213 | Feb 2026 → Feb 2027 expected | small cell lung carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DART-NK01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07480213 ↗ |
| Modality | Cell therapy | “allogeneic dual-target CAR-NK cell products” NCT07480213 ↗ |
| Target | DLL3 | “Directed Against DLL3, CD56 (NCAM1), and/or GD2” NCT07480213 ↗ |
| Target | NCAM1 | “Directed Against DLL3, CD56 (NCAM1), and/or GD2” NCT07480213 ↗ |